Stratmann Stacy L, Kuhn Joseph A, Bell Miller S, Preskitt John T, O'Brien John C, Gable Dennis R, Stephens Jeffrey S, McCarty Todd M
Department of Surgery, Baylor University Medical Center, Dallas, TX, USA.
Am J Surg. 2002 Dec;184(6):578-81; discussion 581. doi: 10.1016/s0002-9610(02)01055-3.
The quick intraoperative parathyroid assay (qPTH) has been proposed as an effective tool in the surgical management of hyperparathyroidism. This assay may facilitate directed, unilateral exploration for uniglandular disease; however, its role in the management of multiglandular disease remains unclear. The purpose of this study is to evaluate the use of qPTH in parathyroid surgery, and to compare the results for uniglandular and multiglandular disease.
A prospective analysis of 63 consecutive patients explored for hyperparathyroidism using the qPTH assay was performed. Preoperative localization studies including ultrasonography and sestamibi scan were routinely obtained. Blood samples for qPTH were routinely drawn prior to the surgical incision, prior to gland excision, as well as 5 and 10 minutes after gland excision. Patients with primary or secondary hyperplasia had blood samples drawn relative to a 3-1/2 gland resection. Additional samples were drawn as needed for patients with a double adenoma. A qPTH decline of greater than or equal to 50% of the highest preincision or gland preexcision level was considered successful. Unilateral neck exploration was routinely performed unless multiglandular disease was identified. Patients were followed up postoperatively with serum calcium levels and an 8-month median follow-up was recorded.
Forty-nine of 63 (78%) patients were found to have a solitary parathyroid adenoma. The qPTH assay was successful in 48 (97%) patients with uniglandular disease. Forty-four of these 48 patients showed an appropriate assay decline 5 minutes after adenoma excision. One patient with a single adenoma showed a delayed 50% decline in qPTH at 20 minutes. Fourteen (22%) patients were found to have multiglandular disease: 6 patients with primary hyperplasia, 4 patients with hyperplasia secondary to renal failure, and 4 patients with double adenomas. All patients with multiglandular disease demonstrated a successful decrease in qPTH levels. All patients with hyperplasia secondary to renal failure showed a successful assay decline 5 minutes after 3-1/2 gland resection. Eight of 14 (57%) patients with multiglandular disease (4 double adenomas, and 4 hyperplasia) were suspected to have solitary adenomas preoperatively. Overall, 62 of 63 (98%) patients showed an appropriate assay decline within 10 minutes after gland excision. Postoperatively, all patients were normocalcemic with a median follow-up of 8 months.
These data suggest that qPTH can accurately facilitate unilateral, directed neck exploration for uniglandular parathyroid disease, as well as guide the extent of gland resection for multiglandular disease. This assay reliably eliminates the most common cause of parathyroidectomy failure, which is unrecognized multiglandular disease. The qPTH assay can reliably be used with similar accuracy for patients with multiglandular disease as has been shown for uniglandular parathyroid disease.
术中快速甲状旁腺激素测定(qPTH)已被认为是甲状旁腺功能亢进症外科治疗中的一种有效工具。该测定可能有助于针对单腺体疾病进行有针对性的单侧探查;然而,其在多腺体疾病管理中的作用仍不明确。本研究的目的是评估qPTH在甲状旁腺手术中的应用,并比较单腺体和多腺体疾病的结果。
对63例连续接受qPTH测定以探查甲状旁腺功能亢进症的患者进行前瞻性分析。常规进行术前定位检查,包括超声检查和锝[99mTc]甲氧基异丁基异腈扫描(sestamibi扫描)。在手术切口前、腺体切除前以及腺体切除后5分钟和10分钟常规采集用于qPTH检测的血样。原发性或继发性增生患者的血样采集相对于3.5腺体切除。对于双腺瘤患者,根据需要采集额外的血样。qPTH下降幅度大于或等于切口前或腺体切除前最高水平的50%被认为是成功的。除非确定为多腺体疾病,否则常规进行单侧颈部探查。术后对患者进行血清钙水平随访,并记录中位随访时间为8个月。
63例患者中有49例(78%)被发现患有孤立性甲状旁腺腺瘤。qPTH测定在48例(97%)单腺体疾病患者中成功。这48例患者中有44例在腺瘤切除后5分钟显示出适当的测定下降。1例单腺瘤患者在20分钟时qPTH延迟下降50%。14例(22%)患者被发现患有多腺体疾病:6例原发性增生患者,4例肾衰竭继发性增生患者,4例双腺瘤患者。所有多腺体疾病患者的qPTH水平均成功下降。所有肾衰竭继发性增生患者在3.5腺体切除后5分钟显示出成功的测定下降。14例多腺体疾病患者中有8例(57%)(4例双腺瘤和4例增生)术前被怀疑患有孤立性腺瘤。总体而言,63例患者中有62例(98%)在腺体切除后10分钟内显示出适当的测定下降。术后,所有患者血钙正常,中位随访时间为8个月。
这些数据表明,qPTH可以准确地促进对单腺体甲状旁腺疾病进行单侧、有针对性的颈部探查,并指导多腺体疾病的腺体切除范围。该测定可靠地消除了甲状旁腺切除术失败的最常见原因,即未被识别的多腺体疾病。qPTH测定对于多腺体疾病患者可以可靠地以与单腺体甲状旁腺疾病相似的准确性使用。